Rules 4.7.3 and 4.10.3 ASX Listing Rules App end ix 4G (curren t at 17/7/2020) Pag e 1 Appendix 4G Key to Disclosures Corporate Governance Council Principles and Recommendations Name of entity RACURA ONCOLOGY LIMITED ABN/ARBN Financial year ended: 61 149 318 749 30 JUNE...
Appendix 4G
Filed with ASX ·
On 6ix: 6ix.com/news/appendix-4g-216
6ix hasn’t read this filing yet.
Earlier from Racura Oncology
- Appendix 4E & Annual Report
- First HARNESS-1 Patient Safely Treated with RC220
- Racure Oncology Techknow Invest Presentation
- June 2026 Quarterly Activities Report and Appendix 4C
- Bellberry Ethics Approval Activates New HARNESS Trial Sites
Later from Racura Oncology
- Corporate Governance Statement
- CPACS Trial Opens for RC220 Patient Enrolment in Korea
- Notification regarding unquoted securities - RAC
- Racura Oncology Adelaide Investor Briefing
- RC220 MYC-silencing data to be presented FCS 26 conference
Follow Racura Oncology into a list and get an email when it puts out news.
Follow Racura Oncology